PTPRB inhibition has been previously studied as a potential therapeutic intervention in vascular disease (Shen et al., 2014), and the PTPRB inhibitor AKB-9778 is currently undergoing clinical trials for treatment of diabetic macular edema, where it is well-tolerated by patients (Campochiaro et al., 2016). The gene discussed is PTPRB; the disease is diabetic macular edema.